Ensysce Biosciences 2025 Q2 Earnings 76.4% EPS Improvement Amid Sustained Losses

Ensysce Biosciences (ENSC) reported its fiscal 2025 Q2 earnings on August 13th, 2025, showcasing a significant improvement in its earnings performance.

Ensysce Biosciences (ENSC) reported a 654.4% year-over-year increase in revenue for Q2 2025, with total revenue rising to $1.37 million from $181,797 in the same period in 2024. The company’s MPAR segment contributed the entirety of this revenue, reflecting a concentration in its core therapeutic platform.

The company’s earnings improved substantially, with a 76.4% reduction in per-share loss to $0.79 in Q2 2025, compared to a loss of $3.35 per share in Q2 2024. Additionally, Ensysce narrowed its net loss to $1.73 million, a 11.9% reduction from $1.97 million a year earlier. Despite this progress, the company has reported losses for five consecutive years in the same quarter, underscoring ongoing financial challenges.

The stock price of Ensysce Biosciences edged up 2.87% on the latest trading day, gained 1.42% over the past week, and declined 2.27% month-to-date.

The post-earnings price action review revealed a highly unfavorable outcome for a buy-and-hold strategy following the earnings report. Over the past three years, purchasing shares on the report date and holding for 30 days yielded a return of -99.89%, significantly underperforming the benchmark by 146.21%. The strategy’s Sharpe ratio of -0.46 highlighted its high-risk profile, while the maximum drawdown of 0% indicated full liquidation at the lowest point.

Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences, emphasized the company’s momentum in Q2 2025, particularly in its next-generation opioid therapy development. She highlighted the initiation of the pivotal Phase 3 trial for PF614 as a key step toward regulatory approval, with the potential to redefine opioid treatment. The full enrollment of Part 2 of the PF614-MPAR-102 study and continued support from NIDA were also noted as significant milestones. The CEO expressed confidence in the advancement of the company’s TAAP™, MPAR®, and OUD programs, underscoring its mission to innovate safer opioid therapies for pain and addiction treatment.

The company remains focused on advancing clinical and regulatory milestones across its pipeline, including the PF614 Phase 3 trial and the PF614-MPAR-102 study, with ongoing non-clinical development in chronic pain applications. Ensysce continues its collaboration with Rho, Inc. and benefits from the FDA Breakthrough Therapy designation and NIDA funding. While no explicit financial guidance was provided, the company anticipates maintaining progress toward its clinical objectives and regulatory goals in the second half of 2025.

Additional News
Bitcoin reached an all-time high of over $124,000 driven by favorable U.S. legislation and rising equities. In Nigeria, the Federal Government announced a seven-year moratorium on new federal universities and tertiary institutions to address underutilized facilities. Cross River State authorities successfully rescued quarry workers, including Indian nationals, who were held hostage by armed youths. In a separate development, Nigeria plans to temporarily close its border with Niger Republic ahead of by-elections to prevent cross-border crimes and maintain electoral integrity.